In vivo studies on the oridonin-loaded nanostructured lipid carriers

Figures & data

Figure 1.  Chemical structure of ORI.

Figure 2.  TEM photograph of freeze-dried ORI-NLC.

Figure 3.  The size distribution of ORI-NLC.

Figure 4.  In vitro release profile of ORI from ORI-NLC (n = 3).

Table 1.  AUC, MRT and re values in different tissues of mice after i.v. administration of ORI-Sol and ORI-NLC with dose of 25 mg/kg.

Organ	AUC0~∞ (h·mg·kg^−1)	MRT(0-t) (h)	re
ORI solution
Heart	245.181	15.570
Liver	94.020	21.243
Spleen	300.209	17.952
Lung	189.838	13.890
Kidney	246.517	28.751
ORI-NLC
Heart	279.810	20.393	1.1
Liver	810.353	39.960	8.6
Spleen	724.530	19.971	2.4
Lung	505.107	21.083	2.7
Kidney	91.340	22.169	0.4

r_e: relative uptake rate equivalent AUC(NLC)/AUC(Sol).

Figure 5.  Mean ORI concentration–time profiles in organs after intravenous administration of ORI solution and ORI-NLC to mice with dose of 25.0 mg/kg.

Figure 6.  ORI tissue concentration percentage of plasma, heart, liver, spleen, lung and kidney at 12 h following i.v. administration of ORI solution and ORI-NLC.

Table 2.  Pharmacokinetic parameters of two-compartmental model following i.v. administration of ORI-Sol and ORI-NLC to mice with dose of 25 mg/kg.

Parameter	Unit	ORI-Sol	ORI-NLC
AUC	h mg·L^−1	62.375	182.278
MRT	h	5.575	11.913
t1/2	h	8.003	11.044
Vd	L·kg^−1	4.514	2.092
CL	L·h^−1·kg^−1	0.391	0.131